Literature DB >> 31097631

Clonal sequence tracking reveals TET2-mutated extranodal NK/T-cell lymphoma disseminated independent of Epstein Barr virus.

Chang-Tsu Yuan1,2, Tai-Chung Huang3, Chi-Chen Chuang4, Yi-Kuang Chuang4, Jia-Huei Tsai1,5, Jau-Yu Liau1,5, Chung-Wu Lin1,5, Jih-Luh Tang6,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31097631      PMCID： PMC6886425          DOI： 10.3324/haematol.2018.215327

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  14 in total

1.  TET2 and DNMT3A mutations in human T-cell lymphoma.

Authors:  Lucile Couronné; Christian Bastard; Olivier A Bernard
Journal:  N Engl J Med       Date:  2012-01-05       Impact factor: 91.245

2.  Loss of Epstein-Barr virus-encoded RNA expression in cutaneous dissemination of natural killer/T-cell lymphoma.

Authors:  Wan-Lin Teo; Soo-Yong Tan
Journal:  J Clin Oncol       Date:  2011-01-31       Impact factor: 44.544

3.  Epstein Barr Virus Infection Can be a Secondary Event in B-Cell Lymphomas: A Review of 338 Cases and a Novel Finding of Zonal EBER+ Tumor Cells Showing Features of Progression From Underlying EBV-negative Lymphoma.

Authors:  Ira J Miller
Journal:  Appl Immunohistochem Mol Morphol       Date:  2019-03

4.  Activating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cells.

Authors:  Can Küçük; Bei Jiang; Xiaozhou Hu; Wenyan Zhang; John K C Chan; Wenming Xiao; Nathan Lack; Can Alkan; John C Williams; Kendra N Avery; Pınar Kavak; Anna Scuto; Emel Sen; Philippe Gaulard; Lou Staudt; Javeed Iqbal; Weiwei Zhang; Adam Cornish; Qiang Gong; Qunpei Yang; Hong Sun; Francesco d'Amore; Sirpa Leppä; Weiping Liu; Kai Fu; Laurence de Leval; Timothy McKeithan; Wing C Chan
Journal:  Nat Commun       Date:  2015-01-14       Impact factor: 14.919

5.  EBV-negative Aggressive NK-cell Leukemia/Lymphoma: Clinical, Pathologic, and Genetic Features.

Authors:  Alina Nicolae; Karthik A Ganapathi; Trinh Hoc-Tran Pham; Liqiang Xi; Carlos A Torres-Cabala; Nahid M Nanaji; Hongbin D Zha; Zhen Fan; Sybil Irwin; Stefania Pittaluga; Mark Raffeld; Elaine S Jaffe
Journal:  Am J Surg Pathol       Date:  2017-01       Impact factor: 6.394

6.  Peripheral T-cell lymphoma with progression to a clonally related, Epstein Barr virus+, cytotoxic aggressive T-cell lymphoma: evidence for secondary EBV infection of an established malignant T-cell clone.

Authors:  Rupert Langer; Eva Geissinger; Thomas Rüdiger; Christoph von Schilling; German Ott; Sonja Mandl-Weber; Leticia Quintanilla-Martinez; Falko Fend
Journal:  Am J Surg Pathol       Date:  2010-09       Impact factor: 6.394

7.  EBV-negative aggressive NK-cell leukemia/lymphoma: a clinical and pathological study from a single institution.

Authors:  Juehua Gao; Amir Behdad; Peng Ji; Kristy L Wolniak; Olga Frankfurt; Yi-Hua Chen
Journal:  Mod Pathol       Date:  2017-05-26       Impact factor: 7.842

8.  PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase.

Authors:  Yok-Lam Kwong; Thomas S Y Chan; Daryl Tan; Seok Jin Kim; Li-Mei Poon; Benjamin Mow; Pek-Lan Khong; Florence Loong; Rex Au-Yeung; Jabed Iqbal; Colin Phipps; Eric Tse
Journal:  Blood       Date:  2017-02-10       Impact factor: 22.113

Review 9.  Epstein-barr virus and the pathogenesis of T and NK lymphoma: a mystery unsolved.

Authors:  Lindsay C George; Martin Rowe; Christopher P Fox
Journal:  Curr Hematol Malig Rep       Date:  2012-12       Impact factor: 3.952

10.  Unveiling Another Missing Piece in EBV-Driven Lymphomagenesis: EBV-Encoded MicroRNAs Expression in EBER-Negative Burkitt Lymphoma Cases.

Authors:  Lucia Mundo; Maria R Ambrosio; Matteo Picciolini; Giuseppe Lo Bello; Sara Gazaneo; Leonardo Del Porro; Stefano Lazzi; Mohsen Navari; Noel Onyango; Massimo Granai; Cristiana Bellan; Giulia De Falco; Davide Gibellini; Pier P Piccaluga; Lorenzo Leoncini
Journal:  Front Microbiol       Date:  2017-03-01       Impact factor: 5.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.